Cas:136309-04-1 6-methylpyrazine-2-carbonitrile manufacturer & supplier

We serve Chemical Name:6-methylpyrazine-2-carbonitrile CAS:136309-04-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

6-methylpyrazine-2-carbonitrile

Chemical Name:6-methylpyrazine-2-carbonitrile
CAS.NO:136309-04-1
Synonyms:6-methyl-2-pyrazinecarbonitrile;2-CYANO-6-METHYLPYRAZINE
Molecular Formula:C6H5N3
Molecular Weight:119.12400
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:49.57000
Exact Mass:119.04800
LogP:0.65668

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 6-methyl-2-pyrazinecarbonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-CYANO-6-METHYLPYRAZINE physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-methyl-2-pyrazinecarbonitrile Use and application,2-CYANO-6-METHYLPYRAZINE technical grade,usp/ep/jp grade.


Related News: Plexxikon filed a lawsuit against the pharma giant in 2017, alledging that Tafinlar, a rival to its melanoma drug Zelboraf that was brought to market in collaboration with Roche, has stepped on its intellectual property. The jury ruled in its favor, adding that the infringement is in fact willful. N,N-dibenzyl-4-(5,6-dimethoxy-2H-benzo[d][1,2,3]triazol-2-yl)aniline manufacturers Novadiscovery (NOVA), a leading health tech company using in silico clinical trials to predict drug efficacy and optimize clinical trial development, today announces the appointment of Grégoire Boutonnet as Chief Operating Officer, effective immediately. 2-Chloro-4-[(E)-4-iodo-phenylimino]-cyclohexa-2,5-dienone suppliers Earlier this month, the drugmaker lifted a voluntary EU marketing hold on Zynteglo for beta thalassemia, after a patient death in one of the drugmaker’s other products, LentiGlobin, halted clinical studies. 2-amino-5-nitro-6-((4-phenylbutyl)amino)pyrimidin-4(3H)-one vendor & factory “The acquisition of Vanamali Organics represents the next stage of this investment strategy,” Wavelength CEO Iftach Seri said in a statement. ” We are delighted to add their talented team and advanced development and manufacturing capabilities to Wavelength, and we expect they will be important contributors to our global supply chain network and our rapidly growing custom development and manufacturing services business.”,“The acquisition of Vanamali Organics represents the next stage of this investment strategy,” Wavelength CEO Iftach Seri said in a statement. ” We are delighted to add their talented team and advanced development and manufacturing capabilities to Wavelength, and we expect they will be important contributors to our global supply chain network and our rapidly growing custom development and manufacturing services business.”